444 related articles for article (PubMed ID: 18071944)
1. Therapeutic anti-VEGF antibodies.
Lien S; Lowman HB
Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
3. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
Barzelay A; Lowenstein A; George J; Barak A
Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
[TBL] [Abstract][Full Text] [Related]
4. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
5. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
6. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
7. [Avastin is not the same as Lucentis, and Lucentis is not the same as Avastin].
Asensio-Sánchez VM
Arch Soc Esp Oftalmol; 2009 Sep; 84(9):427. PubMed ID: 19809922
[No Abstract] [Full Text] [Related]
8. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
Abouammoh M; Sharma S
Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
[TBL] [Abstract][Full Text] [Related]
9. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
[TBL] [Abstract][Full Text] [Related]
10. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
11. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
Dixon JA; Oliver SC; Olson JL; Mandava N
Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
[TBL] [Abstract][Full Text] [Related]
12. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study.
Costa R; Carneiro A; Rocha A; Pirraco A; Falcão M; Vasques L; Soares R
J Cell Biochem; 2009 Dec; 108(6):1410-7. PubMed ID: 19859900
[TBL] [Abstract][Full Text] [Related]
14. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
Grépin R; Pagès G
J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor.
Ferrara N
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):789-91. PubMed ID: 19164810
[TBL] [Abstract][Full Text] [Related]
17. [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment].
Wylegała E; Teper SJ
Klin Oczna; 2007; 109(1-3):97-100. PubMed ID: 17687925
[TBL] [Abstract][Full Text] [Related]
18. Treating age-related macular degeneration - interaction of VEGF-antagonists with their target.
Klettner A; Roider J
Mini Rev Med Chem; 2009 Aug; 9(9):1127-35. PubMed ID: 19689408
[TBL] [Abstract][Full Text] [Related]
19. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW; Adamis AP
Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M
Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
